deltatrials
Unknown PHASE3 NCT00066898

ARISE - Aggressive Reduction of Inflammation Stops Events

Reduction of Vascular Inflammation and Coronary Atherosclerosis With AGI-1067, a V-Protectant, Reduces Cardiovascular Events in Patients With Coronary Artery Disease

Sponsor: AtheroGenics

Conditions Atherosclerosis Coronary Artery Disease Myocardial Infarction Unstable Angina
Interventions AGI-1067
Updated 7 times since 2017 Last updated: Sep 29, 2006 Started: Jun 30, 2003 Completion: Dec 31, 2006

A PHASE3 clinical study on Atherosclerosis and Coronary Artery Disease, this trial is ongoing. The trial is conducted by AtheroGenics and has accumulated 7 data snapshots since 2003. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE3

  5. Sep 2020 — Jan 2021 [monthly]

    Unknown Status PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Sep 2020 [monthly]

    Unknown Status PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE3

    First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AtheroGenics
Data source: AtheroGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom, Abington, United States, Akron, United States, Allentown, United States, Amarillo, United States, Appleton, United States, Arcadia, South Africa, Atlanta, United States, Auburn, United States, Austin, United States and 171 more location s